Table 1.
Baseline clinical characteristics of patients with early RA enrolled into SWEFOT, divided by survivin status
| Variables | Survivin-positive | Survivin-negative | P value |
|---|---|---|---|
| n = 114 | n = 188 | ||
| Age (years) | 56.0 (43.0, 62.25) | 57.0 (44.0, 67.0) | 0.332 |
| Sex (F) | 77 (68 %) | 143 (76 %) | 0.107 |
| Duration | 5.0 (4.0, 8.0) | 5.0 (4.0, 8.75) | 0.905 |
| RF (+) | 91/113 (81 %) | 108/187 (58 %) | <0.001 |
| Anti-CCP (+) | 71/107 (66 %) | 103/183 (56 %) | 0.091 |
| Pain-VAS | 60.0 (45.75, 72.0) | 54.0 (39.0, 71.0) | 0.269 |
| PtGA-VAS | 60.0 (39.0, 77.0) | 58.0 (35.25, 74.0) | 0.452 |
| HAQ | 1.25 (0.85, 1.75) | 1.0 (0.75, 1.5) | 0.079 |
| TJC | 8.0 (5.0, 13.0) | 9.5 (6.0, 14.0) | 0.134 |
| SJC | 11.0 (6.0, 14.0) | 10.0 (7.0, 14.0) | 0.692 |
| ESR | 35.0 (21.5, 63.0)a | 34.0 (19.25, 50.0) | 0.260 |
| CRP | 17.0 (9.0, 54.5)a | 18.0 (9.0, 37.0) | 0.628 |
| DAS28 | 5.78 (5.06, 6.35)a | 5.72 (5.02, 6.43) | 0.751 |
aNumber of patients, n = 113. Serum levels of survivin >0.45 ng/mL indicate survivin-positive patients. Statistics in the groups are presented as medians and interquartile range (IQR). Comparisons between the groups were done by Mann–Whitney U tests for continuous variables, and by Pearson’s χ 2 tests for frequencies. Anti-CCP, antibodies to cyclic citrullinated peptides; CRP, C-reactive protein; DAS28, 28-joint count disease activity score; ESR, erythrocyte sedimentation rate; F, females; HAQ, Health Assessment Questionnaire; pain-VAS, visual analog scale for pain; PtGA-VAS, patient’s global assessment of disease activity; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count